LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

LLY

1,021.31

-0.16%↓

JNJ

210.71

+0.31%↑

ABBV

221.72

-1.34%↓

UNH

342.2

+2.84%↑

AZN

89.62

-1.82%↓

Home・Aandelen Lijst・Avita Therapeutics Inc

Avita Therapeutics Inc

Gesloten

3.5 -0.28

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.4

Max

3.57

Belangrijke statistieken
By Trading Economics
Inkomsten	-3.3M -13M
Verkoop	-1.4M 17M
EPS	-0.712
Winstmarge	-77.289
Werknemers	260
EBITDA	4M -8.1M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+85.71% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-16M 105M
Vorige openingsprijs	3.78
Vorige sluitingsprijs	3.5

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

8.83 / 9.77 Steun & Weerstand

Avita Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2025, 23:58 UTC

Acquisities, Fusies, Overnames

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dec 2025, 23:56 UTC

Winsten

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dec 2025, 23:03 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Winsten

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dec 2025, 23:45 UTC

Marktinformatie

Global Equities Roundup: Market Talk

11 dec 2025, 23:44 UTC

Marktinformatie

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dec 2025, 23:37 UTC

Marktinformatie

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dec 2025, 23:31 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 22:48 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dec 2025, 22:35 UTC

Winsten

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dec 2025, 22:30 UTC

Winsten

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dec 2025, 22:09 UTC

Acquisities, Fusies, Overnames

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dec 2025, 22:06 UTC

Acquisities, Fusies, Overnames

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dec 2025, 22:05 UTC

Winsten

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dec 2025, 21:51 UTC

Acquisities, Fusies, Overnames

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dec 2025, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

11 dec 2025, 21:39 UTC

Winsten

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dec 2025, 21:39 UTC

Winsten

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dec 2025, 21:38 UTC

Winsten

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dec 2025, 21:37 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dec 2025, 21:37 UTC

Marktinformatie

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dec 2025, 21:34 UTC

Acquisities, Fusies, Overnames

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dec 2025, 21:29 UTC

Acquisities, Fusies, Overnames

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dec 2025, 21:28 UTC

Marktinformatie

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

Dexus: Third Party Investors to Contribute Remainder

11 dec 2025, 21:27 UTC

Acquisities, Fusies, Overnames

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dec 2025, 21:25 UTC

Acquisities, Fusies, Overnames

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Peer Vergelijking

Prijswijziging

Avita Therapeutics Inc Prognose

Koersdoel

By TipRanks

85.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6.5 USD 85.71%

Hoogste 11 USD

Laagste 3 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avita Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Avita Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.83 / 9.77Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.